Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PAM | P19021 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30886860 | 1.00 | DGKA (0.36) | DGKANR4A1TDP1PAMPRKCA | |
| SCHEMBL5155355 | 0.93 | DGKA (0.41) | DGKANR4A1TDP1PAMELANE | |
| SCHEMBL31542572 | 0.86 | TDP1 (0.41) | DGKATDP1PAMELANEKMT2A | |
| SCHEMBL20581979 | 0.83 | TDP1 (0.38) | TDP1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6266333 | 0.82 | CA2 (0.46) | MAPT | |
| SCHEMBL4971394 | 0.81 | KDM4E (0.43) | DGKAKMT2ANPC1RAB9ASMN1; SMN2 | |
| Acetic Acid SCHEMBL6266322 | 0.80 | CA2 (0.44) | MAPT | |
| SCHEMBL483438 | 0.78 | DGKA (0.43) | DGKANR4A1TDP1PAMELANE | |
| SCHEMBL2905259 | 0.78 | DGKA (0.43) | DGKANR4A1TDP1PAMELANE | |
| SCHEMBL21090601 | 0.78 | CA2 (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2014-12-18 | — | — | US | claimed |
| US-20120121724-A1 | FILM COMPRISING THERAPEUTIC AGENTS | MAIBACH TODD (US) | 2012-05-17 | — | — | US | claimed |
| US-20070059346-A1 | Film comprising therapeutic agents | ACADERM, INC. | 2007-03-15 | — | — | US | claimed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000065024-A2 | HYPERBRANCHED POLYMERIC MICELLES FOR ENCAPSULATION AND DELIVERY OF HYDROPHOBIC MOLECULES | RUTGERS, THE STATE UNIVERSITY (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | DGKA 2877/4885NR4A1 2099/4885TDP1 1443/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | DGKA 4276/4885NR4A1 348/4885TDP1 4136/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | DGKA 4062/4885NR4A1 377/4885TDP1 3753/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | DGKA 4143/4885NR4A1 541/4885TDP1 3910/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | DGKA 4143/4885NR4A1 541/4885TDP1 3910/4885 |
| US-20140370110-A1 | POLYMER CONJUGATED PROTEIN MICELLES | MTDH, PSMG3, GHITM | DGKA 3620/4885NR4A1 4337/4885TDP1 3662/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | DGKA 1387/4885NR4A1 1469/4885TDP1 1453/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | DGKA 2972/4885NR4A1 2055/4885TDP1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.